Azithromycin | Hemomycin powder d / pr suspension for oral administration 200 mg / 5 ml 10 g 1 pc.
Special Price
$17.46
Regular Price
$25.00
In stock
SKU
BID463333
Description
Powder of white or almost white color with a fruity odor. Description of the finished suspension: the suspension is almost white in color with a fruity odor.
Powder of white or almost white color with a fruity odor. Description of the finished suspension: the suspension is almost white in color with a fruity odor.
Description
Powder of white or almost white color with a fruity odor. Description of the finished suspension: the suspension is almost white in color with a fruity odor.
Pharmacological action
Broad-spectrum antibiotic. Azithromycin is a representative of a subgroup of macrolide antibiotics - azalides. In high concentrations it has a bactericidal effect. Chemomycin is active against aerobic gram-positive bacteria: Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus spp. groups C, F and G, Streptococcus viridans, Staphylococcus aureus of aerobic gram-negative bacteria: Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, Bordetella parapertussis, Legionella pneumophila, Haemophiloberioberli bacteri blerloberljeroberioberljeroberi bacteria , Clostridium perfringens, Peptostreptococcus spp. The drug is active against intracellular microorganisms: Chlamydia trachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum, Borrelia burgdorferi, as well as against Treponema pallidum. Gram-positive bacteria resistant to erythromycin are resistant to the drug.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to azithromycin: infections of the upper respiratory tract and ENT organs (sinusitis, tonsillitis, pharyngitis, otitis media) infections of the lower respiratory tract (bacterial and atypical pneumonia, acute bronchitis, obstruction) infections of the skin and soft tissues (moderate acne vulgaris, erysipelas, impetigo, secondarily infected dermatoses) Lyme disease (borreliosis), for the treatment of the initial stage (erythema migrans) infection in the genital tract (urethritis and / or cervicitis), caused by Chlamydia trachomatis.
Use during pregnancy and lactation
During pregnancy, hemomycin is prescribed only when the expected benefit of the therapy to the mother outweighs the potential risk to the fetus.
If you need to use the drug during lactation, you should decide whether to stop breastfeeding while you are using the drug.
Special instructions
If you miss a single dose of the drug, you should take the missed dose as soon as possible, and the subsequent ones with 24 hour intervals. Azithromycin should be taken at least one hour before or two hours after taking the antacid drugs . Azithromycin should be used with caution in patients with impaired liver function of mild to moderate severity due to the possibility of developing fulminant hepatitis and severe renal failure. In the presence of symptoms of impaired liver function, such as rapidly growing asthenia, jaundice, dark urine, a tendency to bleeding, hepatic encephalopathy, drug therapy should be discontinued and a study of the functional state of the liver should be carried out. In case of impaired renal function of mild to moderate severity (creatinine clearance greater than 40 ml / min), azithromycin therapy should be carried out with caution under the control of the state of renal function. As with the use of other antibacterial drugs, patients with azithromycin should be regularly examined for the presence of unresponsive microorganisms and signs of superinfection, including fungal infections. The drug should not be used for longer courses than indicated in the instructions, since the pharmacokinetic properties of azithromycin make it possible to recommend a short and simple dosage regimen. There is no data on the possible interaction between azithromycin and derivatives of ergotamine and dihydroergotamine, but due to the development of ergotism with the simultaneous use of macrolides with derivatives of ergotamine and dihydroergotamine, this combination is not recommended. With prolonged use of azithromycin, the development of pseudomembranous colitis caused by Clostridium difficile is possible, as in the form of mild diarrhea against the background of the prima drug, and also 2 months after the end of therapy, clostridial pseudomembranous colitis should be excluded. When treated with macrolides, including azithromycin, an increase in cardiac repolarization and QT intralum was observed, increasing the risk of developing cardiac arrhythmias, including pirouette type arrhythmias, which can lead to cardiac arrest. Caution should be exercised when using the drug in patients with proarrhythmogenic factors (especially in elderly patients), including with a congenital or acquired extended QT interval in patients receiving therapy with drugs of classes IA (quinidine, procainamide), III (dofetilide, amiodarone and sotalol), cisapride, terfenadine, antipsychotic drugs (citalopram), fluoroquinolones (moxifloxacin) and levofloxacin with impaired water-electrolyte balance, especially in the case of hypokalemia or hypomagnesemia, with clinically significant bradycardia, cardiac arrhythmias, or severe heart failure. The use of azithromycin can provoke the development of myasthenic syndrome or cause an exacerbation of myasthenia gravis. Influence on the ability to drive vehicles and mechanisms In connection with the possible development of undesirable reactions from the central nervous system during treatment, care must be taken when driving vehicles and performing other activities that require an increased concentration of attention and speed of psychomotor reactions.
Dosage and administration
The drug is taken orally 1 time per day 1 hour before meals or 2 hours after meals. Water (distilled or boiled and chilled) is added to the vial to the mark. The contents of the vial are thoroughly shaken until a homogeneous suspension is obtained.
Side effects
Hypersensitivity to azithromycin or other components of the drug hypersensitivity to erythromycin, other macrolides, ketolides concomitant use with ergotamine, dihydroergotamine severe liver function impairment of severe renal function (40 ml / min creatinine clearance less than) children's age up to 12 months. With caution Myasthenia gravis, impaired liver function of mild to moderate severity, impaired renal function of mild to moderate severity (creatinine clearance greater than 40 ml / min), in patients with proarrhythmogenic factors (especially in elderly patients): with congenital or acquired prolongation of the interval QT, in patients receiving antiarrhythmic drugs of classes IA (quinidine, procainamide) and III (dofetilide, amiodarone and sotalol), cisapride, terfenadine, antipsychotic drugs (citalopram), fluoroquinolones (moxif loxacin and levofloxacin), with impaired water-electrolyte balance, especially in the case of hypokalemia or hypomagnesemia, with clinically significant bradycardia, cardiac arrhythmias or severe heart failure, simultaneous use of digoxin, warfarin, cyclosporine pregnancy.
Drug interactions
Antacids (aluminum and magnesium) do not affect the bioavailability of azithromycin, but reduce its maximum concentration in the blood by about 25%, so the drug should be taken at least one hour before or two hours after taking these preparations.
Food slows down and decreases absorption.
When combined with the anticoagulants of the indirect action of the coumarin series (warfarin), the anticoagulation effect may be enhanced, patients need careful monitoring of prothrombin time.
Digoxin: possibly increasing the concentration of digoxin is necessary to control the concentration of digoxin in the blood.
Ergotamine and dihydroergotamine: increased toxic effects (vasospasm, dysesthesia) combined use is not recommended.
The simultaneous use of terfenadine and antibiotics of the macrolide class causes arrhythmia and lengthening of the QT interval. It is necessary to take these data into account while using terfenadine and azithromycin.
With the simultaneous use of fluconazole reduces the maximum concentration of azithromycin in the blood by 18%, which does not have clinical significance.
Cases of rhabdomyolysis have been reported in patients simultaneously taking azithromycin and statins.
With the simultaneous use of azithromycin and rifabutin, neutropenia was sometimes observed. Although neutropenia has been associated with rifabutin, a causal relationship between the use of a combination of azithromycin and rifabutin and neutropenia has not been established.
With the simultaneous use of azithromycin and cyclosporine, it is necessary to control the concentration of cyclosporin in the blood plasma and adjust the dose accordingly.
With simultaneous use with zidovudine, azithromycin has a slight effect on the pharmacokinetics, including excretion by the kidneys, zadovudine and its glucuronide metabolite, however, the concentration of the active metabolite, phosphorylated zidovudine, in mononuclear cells of peripheral blood increases (the clinical significance of this fact has not been determined).
The simultaneous use of azithromycin (1200 mg) and nelfinavir (750 mg 3 times a day) causes an increase in the equilibrium concentration of azithromycin in blood plasma. Clinically significant side effects were not observed and dose adjustment of azithromycin with its simultaneous use with nelfinavir is not required.
Azithromycin weakly interacts with cytochrome P450 isoenzymes. It was not found that azithromycin is involved in pharmacokinetic interactions similar to erythromycin and other macrolides, azithromycin is not an inducer and inhibitor of cytochrome P450 isoenzymes.
In pharmacokinetic studies of the effect of a single dose of cimetidine on the pharmacokinetics of azithromycin, no pharmacokinetics of azithromycin were detected, provided cimetidine was used 2 hours before azithromycin.
Azithromycin does not affect the plasma concentration of carbamazepine, efavirenz, didanosine, fluconazole, indinavir, cetirizine, midazoles, theophylline, triazolam, nelfinavir, trimethoprim / sulfamethoxazole, sildenafil, atorvastatin, methylprednisolone with simultaneous use.
Overdose
Symptoms: severe nausea, temporary hearing loss, vomiting, diarrhea.
Treatment: symptomatic gastric lavage.
Storage Conditions
Store in a dry, dark place at 15 to 25 РC. Keep out of reach of children.
Expiration
3 years. Do not use after the expiry date stated on the packaging.
Active ingredient
Azithromycin
drugstore conditions
drugstore
oral suspension
Prescribing
For children older than 6 months, For children prescribed by the doctor
Indications
Indications
Bronchitis, Low learning, Inflammation of the lungs, Bronchitis bronchitis From pneumonia, From sinusitis, From skin infections, From infectious diseases, From pharyngitis, From otitis media, From sinusitis, From respiratory infections, From tonsillitis, From sore throat
Powder of white or almost white color with a fruity odor. Description of the finished suspension: the suspension is almost white in color with a fruity odor.
Pharmacological action
Broad-spectrum antibiotic. Azithromycin is a representative of a subgroup of macrolide antibiotics - azalides. In high concentrations it has a bactericidal effect. Chemomycin is active against aerobic gram-positive bacteria: Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus spp. groups C, F and G, Streptococcus viridans, Staphylococcus aureus of aerobic gram-negative bacteria: Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, Bordetella parapertussis, Legionella pneumophila, Haemophiloberioberli bacteri blerloberljeroberioberljeroberi bacteria , Clostridium perfringens, Peptostreptococcus spp. The drug is active against intracellular microorganisms: Chlamydia trachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum, Borrelia burgdorferi, as well as against Treponema pallidum. Gram-positive bacteria resistant to erythromycin are resistant to the drug.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to azithromycin: infections of the upper respiratory tract and ENT organs (sinusitis, tonsillitis, pharyngitis, otitis media) infections of the lower respiratory tract (bacterial and atypical pneumonia, acute bronchitis, obstruction) infections of the skin and soft tissues (moderate acne vulgaris, erysipelas, impetigo, secondarily infected dermatoses) Lyme disease (borreliosis), for the treatment of the initial stage (erythema migrans) infection in the genital tract (urethritis and / or cervicitis), caused by Chlamydia trachomatis.
Use during pregnancy and lactation
During pregnancy, hemomycin is prescribed only when the expected benefit of the therapy to the mother outweighs the potential risk to the fetus.
If you need to use the drug during lactation, you should decide whether to stop breastfeeding while you are using the drug.
Special instructions
If you miss a single dose of the drug, you should take the missed dose as soon as possible, and the subsequent ones with 24 hour intervals. Azithromycin should be taken at least one hour before or two hours after taking the antacid drugs . Azithromycin should be used with caution in patients with impaired liver function of mild to moderate severity due to the possibility of developing fulminant hepatitis and severe renal failure. In the presence of symptoms of impaired liver function, such as rapidly growing asthenia, jaundice, dark urine, a tendency to bleeding, hepatic encephalopathy, drug therapy should be discontinued and a study of the functional state of the liver should be carried out. In case of impaired renal function of mild to moderate severity (creatinine clearance greater than 40 ml / min), azithromycin therapy should be carried out with caution under the control of the state of renal function. As with the use of other antibacterial drugs, patients with azithromycin should be regularly examined for the presence of unresponsive microorganisms and signs of superinfection, including fungal infections. The drug should not be used for longer courses than indicated in the instructions, since the pharmacokinetic properties of azithromycin make it possible to recommend a short and simple dosage regimen. There is no data on the possible interaction between azithromycin and derivatives of ergotamine and dihydroergotamine, but due to the development of ergotism with the simultaneous use of macrolides with derivatives of ergotamine and dihydroergotamine, this combination is not recommended. With prolonged use of azithromycin, the development of pseudomembranous colitis caused by Clostridium difficile is possible, as in the form of mild diarrhea against the background of the prima drug, and also 2 months after the end of therapy, clostridial pseudomembranous colitis should be excluded. When treated with macrolides, including azithromycin, an increase in cardiac repolarization and QT intralum was observed, increasing the risk of developing cardiac arrhythmias, including pirouette type arrhythmias, which can lead to cardiac arrest. Caution should be exercised when using the drug in patients with proarrhythmogenic factors (especially in elderly patients), including with a congenital or acquired extended QT interval in patients receiving therapy with drugs of classes IA (quinidine, procainamide), III (dofetilide, amiodarone and sotalol), cisapride, terfenadine, antipsychotic drugs (citalopram), fluoroquinolones (moxifloxacin) and levofloxacin with impaired water-electrolyte balance, especially in the case of hypokalemia or hypomagnesemia, with clinically significant bradycardia, cardiac arrhythmias, or severe heart failure. The use of azithromycin can provoke the development of myasthenic syndrome or cause an exacerbation of myasthenia gravis. Influence on the ability to drive vehicles and mechanisms In connection with the possible development of undesirable reactions from the central nervous system during treatment, care must be taken when driving vehicles and performing other activities that require an increased concentration of attention and speed of psychomotor reactions.
Dosage and administration
The drug is taken orally 1 time per day 1 hour before meals or 2 hours after meals. Water (distilled or boiled and chilled) is added to the vial to the mark. The contents of the vial are thoroughly shaken until a homogeneous suspension is obtained.
Side effects
Hypersensitivity to azithromycin or other components of the drug hypersensitivity to erythromycin, other macrolides, ketolides concomitant use with ergotamine, dihydroergotamine severe liver function impairment of severe renal function (40 ml / min creatinine clearance less than) children's age up to 12 months. With caution Myasthenia gravis, impaired liver function of mild to moderate severity, impaired renal function of mild to moderate severity (creatinine clearance greater than 40 ml / min), in patients with proarrhythmogenic factors (especially in elderly patients): with congenital or acquired prolongation of the interval QT, in patients receiving antiarrhythmic drugs of classes IA (quinidine, procainamide) and III (dofetilide, amiodarone and sotalol), cisapride, terfenadine, antipsychotic drugs (citalopram), fluoroquinolones (moxif loxacin and levofloxacin), with impaired water-electrolyte balance, especially in the case of hypokalemia or hypomagnesemia, with clinically significant bradycardia, cardiac arrhythmias or severe heart failure, simultaneous use of digoxin, warfarin, cyclosporine pregnancy.
Drug interactions
Antacids (aluminum and magnesium) do not affect the bioavailability of azithromycin, but reduce its maximum concentration in the blood by about 25%, so the drug should be taken at least one hour before or two hours after taking these preparations.
Food slows down and decreases absorption.
When combined with the anticoagulants of the indirect action of the coumarin series (warfarin), the anticoagulation effect may be enhanced, patients need careful monitoring of prothrombin time.
Digoxin: possibly increasing the concentration of digoxin is necessary to control the concentration of digoxin in the blood.
Ergotamine and dihydroergotamine: increased toxic effects (vasospasm, dysesthesia) combined use is not recommended.
The simultaneous use of terfenadine and antibiotics of the macrolide class causes arrhythmia and lengthening of the QT interval. It is necessary to take these data into account while using terfenadine and azithromycin.
With the simultaneous use of fluconazole reduces the maximum concentration of azithromycin in the blood by 18%, which does not have clinical significance.
Cases of rhabdomyolysis have been reported in patients simultaneously taking azithromycin and statins.
With the simultaneous use of azithromycin and rifabutin, neutropenia was sometimes observed. Although neutropenia has been associated with rifabutin, a causal relationship between the use of a combination of azithromycin and rifabutin and neutropenia has not been established.
With the simultaneous use of azithromycin and cyclosporine, it is necessary to control the concentration of cyclosporin in the blood plasma and adjust the dose accordingly.
With simultaneous use with zidovudine, azithromycin has a slight effect on the pharmacokinetics, including excretion by the kidneys, zadovudine and its glucuronide metabolite, however, the concentration of the active metabolite, phosphorylated zidovudine, in mononuclear cells of peripheral blood increases (the clinical significance of this fact has not been determined).
The simultaneous use of azithromycin (1200 mg) and nelfinavir (750 mg 3 times a day) causes an increase in the equilibrium concentration of azithromycin in blood plasma. Clinically significant side effects were not observed and dose adjustment of azithromycin with its simultaneous use with nelfinavir is not required.
Azithromycin weakly interacts with cytochrome P450 isoenzymes. It was not found that azithromycin is involved in pharmacokinetic interactions similar to erythromycin and other macrolides, azithromycin is not an inducer and inhibitor of cytochrome P450 isoenzymes.
In pharmacokinetic studies of the effect of a single dose of cimetidine on the pharmacokinetics of azithromycin, no pharmacokinetics of azithromycin were detected, provided cimetidine was used 2 hours before azithromycin.
Azithromycin does not affect the plasma concentration of carbamazepine, efavirenz, didanosine, fluconazole, indinavir, cetirizine, midazoles, theophylline, triazolam, nelfinavir, trimethoprim / sulfamethoxazole, sildenafil, atorvastatin, methylprednisolone with simultaneous use.
Overdose
Symptoms: severe nausea, temporary hearing loss, vomiting, diarrhea.
Treatment: symptomatic gastric lavage.
Storage Conditions
Store in a dry, dark place at 15 to 25 РC. Keep out of reach of children.
Expiration
3 years. Do not use after the expiry date stated on the packaging.
Active ingredient
Azithromycin
drugstore conditions
drugstore
oral suspension
Prescribing
For children older than 6 months, For children prescribed by the doctor
Indications
Indications
Bronchitis, Low learning, Inflammation of the lungs, Bronchitis bronchitis From pneumonia, From sinusitis, From skin infections, From infectious diseases, From pharyngitis, From otitis media, From sinusitis, From respiratory infections, From tonsillitis, From sore throat
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review